[HTML][HTML] GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma

P Silva-Rodríguez, D Fernández-Díaz, M Bande… - Cancers, 2022 - mdpi.com
Simple Summary The development of uveal melanoma is a multifactorial and multi-step
process, in which specific and recurrent mutations arise early. Among the recurrently …

Ocular melanoma: an overview of the current status

P Jovanovic, M Mihajlovic… - … journal of clinical …, 2013 - pmc.ncbi.nlm.nih.gov
Ocular melanoma is the second most common type of melanoma after cutaneous and the
most common primary intraocular malignant tumor in adults. Large majority of ocular …

TERT Promoter Mutations in Familial and Sporadic Melanoma

S Horn, A Figl, PS Rachakonda, C Fischer, A Sucker… - Science, 2013 - science.org
Cutaneous melanoma occurs in both familial and sporadic forms. We investigated a
melanoma-prone family through linkage analysis and high-throughput sequencing and …

[HTML][HTML] Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry

X Feng, MS Degese, R Iglesias-Bartolome, JP Vaque… - Cancer cell, 2014 - cell.com
Mutually exclusive activating mutations in the GNAQ and GNA11 oncogenes, encoding
heterotrimeric Gαq family members, have been identified in∼ 83% and∼ 6% of uveal and …

Mutations in GNA11 in Uveal Melanoma

CD Van Raamsdonk, KG Griewank… - … England Journal of …, 2010 - Mass Medical Soc
Background Uveal melanoma is the most common intraocular cancer. There are no effective
therapies for metastatic disease. Mutations in GNAQ, the gene encoding an alpha subunit of …

[HTML][HTML] A platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal melanoma oncogene controls the hippo pathway through FAK

X Feng, N Arang, DC Rigiracciolo, JS Lee, H Yeerna… - Cancer cell, 2019 - cell.com
Activating mutations in GNAQ/GNA11, encoding Gαq G proteins, are initiating oncogenic
events in uveal melanoma (UM). However, there are no effective therapies for UM. Using an …

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

CD Van Raamsdonk, V Bezrookove, G Green, J Bauer… - Nature, 2009 - nature.com
BRAF and NRAS are common targets for somatic mutations in benign and malignant
neoplasms that arise from melanocytes situated in epithelial structures, and lead to …

[HTML][HTML] Oncogenic mutations in GNAQ occur early in uveal melanoma

MD Onken, LA Worley, MD Long, S Duan… - … & visual science, 2008 - arvojournals.org
purpose. Early/initiating oncogenic mutations have been identified for many cancers, but
such mutations remain unidentified in uveal melanoma (UM). An extensive search for such …

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

JM Kirkwood, L Bastholt, C Robert… - Clinical Cancer …, 2012 - aacrjournals.org
Purpose: To compare the efficacy and tolerability of the mitogen-activated protein
(MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus …

Uveal melanoma

F Spagnolo, G Caltabiano, P Queirolo - Cancer treatment reviews, 2012 - Elsevier
Uveal melanoma, which arises from melanocytes residing in the stroma, is the most common
primary intraocular tumor in adults. Up to 50% of patients with primary uveal melanoma will …